Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.
This Phase I trial is seeking to understand the recommended dose of a targeted therapy (BGB-16673) in people with B-Cell Malignancies
Status : Recruiting
This phase III trial is trying to evaluate the safety and effectiveness of a targeted cancer drug, given alone and in combination with another targeted cancer drug or chemotherapy, for the treatment of patients with a colorectal cancer that has spread to other parts of the body
This phase III trial will evaluate whether it is more or less effective to use an immunotherapy, in combination with chemotherapy, to treat women with advanced or recurrent endometrial cancer
This phase III trial is testing the combination of two targeted cancer drugs (Ruxolitinib and Navitoclax) to see if it is better than using one targeted cancer drug (Ruxolitinib) to treat people with myelofibrosis
This phase I trial is trying to determine the best dosing level of a targeted therapy drug (BGB-11417), and assess its effectiveness both by itself and in combination with another targeted therapy (Zanubrutinib)
This Phase I trial is evaluating how safe and tolerable a combination of targeted therapies (Blinatumomab and AMG 404) is in adults with relapsed or refractory B Cell precursor Acute Lymphoblastic Leukaemia
This phase I trial seeks to understand how safe and tolerable an immunotherapy drug (AMG 757) is in people with neuroendocrine prostate cancer
This phase II trial is assessing the effect of adding radiotherapy (stereotactic body radiation therapy - SBRT) to the standard of care treatment immunotherapy (ipilimumab/nivolumab), compared with immunotherapy as a standard alone treatment, in people with metastatic kidney cancer
This phase II trial is trying to understand the safety and effectiveness of targeted therapy drug (trastuzumab deruxtecan) in people with HER2-overexpressing advanced colorectal cancer.
This Phase I/II trial is trying to understand how effective targeted therapy (derazantinib) is alone, or when combined with immunotherapy (atezolizumab) or chemotherapy (paclitaxel) and another targeted therapy (ramucirumab), compared to the standard of care treatment of paclitaxel and ramucirumab in people with HER2-negative gastric adenocarcinoma
Looking for a trial? Use the search functionality to find the trial you are finding.